Search Results

The Cheshire Diagnostics Limited QAß2A IgM Elisa Kit HRP is an Enzyme Linked Immunoassay for the in vitro semiquantitative detection of IgM antibodies to ß2-Glycoprotein-I in human serum. The presence of ß2-GPI antibodies can be used in conjunction with other serological tests and clinical findings to aid in the assessment of the risk from thrombosis in patients with Systemic Lupus Erythematosus or other lupus like disorders.

Not Found

I apologize, but this document does not contain the information requested about acceptance criteria and a study proving device performance. This is a 510(k) clearance letter from the FDA for the QAB2A IgM Elisa Kit HRP, which primarily discusses the regulatory approval process based on substantial equivalence to a predicate device.

The document does not include:

1. A table of acceptance criteria and reported device performance.
2. Details about sample sizes for test sets, data provenance.
3. Information on experts used to establish ground truth or adjudication methods.
4. Any mention of a multi-reader multi-case (MRMC) comparative effectiveness study or human-in-the-loop performance.
5. A standalone algorithm performance study.
6. The type of ground truth used (e.g., pathology, outcomes data).
7. Sample size for the training set or how its ground truth was established.

This document is a formal notification of FDA clearance, indicating that the device has been deemed substantially equivalent to a legally marketed predicate device, allowing it to be marketed. It refers to an "Indications for Use Statement" (on page 2 of the provided text), but this statement defines the intended use of the device, not its performance specifications or the results of a performance study.

Ask a specific question about this device

The Cheshire Diagnostics Limited QAB2A IgM Elisa Kit is a semi quantitative enzyme linked immunoassay for the detection of the IgM isotype autoantibody to ß2-Glycoprotein-1 in human serum. The presence of ß2-GP1 antibodies can be used in conjunction with other serological tests and clinical findings to aid in the assessment of the risk from thrombosis in patients with Systemic Lupus Erythematosus or other Lupus like disorders.

Not Found

The provided document is a 510(k) premarket notification letter from the FDA for a diagnostic kit (QAB2A IgM Elisa Kit AP). It declares the device substantially equivalent to a predicate device but does not contain information about acceptance criteria or specific study details to prove the device meets such criteria. Therefore, I cannot generate the requested information based on the provided text.

Ask a specific question about this device